Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

Journal of Psychopharmacology

Volumn 28, Issue 1, 2014, Pages 62-66

  Hendricks, Peter S ^a   Clark, C Brendan ^b   Johnson, Matthew W ^c   Fontaine, Kevin R ^a   Cropsey, Karen L ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

criminal justice; Hallucinogen; lysergic acid diethylamide; positive psychology; psilocybin; psychedelic; recidivism

Indexed keywords

PSYCHEDELIC AGENT;

ADOLESCENT; ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CONFOUNDING VARIABLE; CRIMINAL JUSTICE; DRUG DEPENDENCE; DRUG WITHDRAWAL; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OFFENDER; PREDICTION; PRIORITY JOURNAL; RECIDIVISM; RISK ASSESSMENT; SOCIAL BEHAVIOR; SUBSTANCE ABUSE; VERY ELDERLY; BEHAVIOR, ADDICTIVE; CRIME; MIDDLE AGED; PREVENTION AND CONTROL; PRISONER; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BEHAVIOR, ADDICTIVE; CRIME; CRIMINALS; HALLUCINOGENS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRISONERS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84891847165     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113513851     Document Type: Article

References (32)

1. Arendsen-Hein GW Hallucinogenic Drugs and Their Psychotherapeutic Use. Crocket RW Sandison RA Walk A, ed. London: H. K. Lewis & Co. Ltd. ; 1963: 101-106.
2. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal. 2012 ; 4: 543-555
3. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012a ; 109: 2138-2143
4. Carhart-Harris RL, Leech R, Williams TM, et al. Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012b ; 200: 238-244
5. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: Improving public health and safety. JAMA. 2009 ; 301: 183-190
6. Doblin R. Dr. Leary's concord prison experiment: A 34-year follow-up study. J Psychoactive Drugs. 1998 ; 30: 419-426 (Pubitemid 29046931)
7. First MB, Spitzer RL, Gibbon M, et al Structured Clinical Interview for DSM-IV-TR Axis I Disorders. New York: Biometrics Research Department, New York State Psychiatric Institute ; 2002:
8. Griffiths RR, Richards WA, Johnson MW, et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008 ; 22: 621-632
9. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 ; 187: 268-283 (Pubitemid 44088380)
10. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 ; 68: 71-78
11. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: Guidelines for safety. J Psychopharmacol. 2008 ; 22: 603-620
12. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol. 2012 ; 26: 994-1002
13. Krupitsky EM, Burakov AM, Dunaevsky IV, et al. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007 ; 39: 13-19 (Pubitemid 46764228)
14. Krupitsky EM, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat. 2002 ; 23: 273-283 (Pubitemid 35477807)
15. Krupitsky EM, Grineko AY, Berkaliev TN, et al. The combination of psychedelic and aversive approaches in alcoholism treatment: The affective contra-attribution method. Alcohol Treat Q. 1992 ; 9: 99-105
16. Leary T. The effects of consciousness-expanding drugs on prisoner rehabilitation. Psychedelic Rev. 1969 ; 10: 29-45
17. Maciulaitis R, Kontrimaviciute V, Bressolle FM, et al. Ibogaine, an anti-addictive drug: Pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol. 2008 ; 27: 181-194
18. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011 ; 25: 1453-1461
19. Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry. 1971 ; 118: 229-230
20. Maruschak LM, Parks E Probation and Parole in the United States, 2011. Washington, DC: US Department of Justice, Bureau of Justice Statistics ; 2012:
21. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181 (Pubitemid 38167565)
22. Pahnke WN, Kurland AA, Unger S, et al. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970 ; 212: 1856-1863
23. Perry A, Coulton S, Glanville J, et al. Interventions for drug-using offenders in the courts, secure establishments and the community. Cochrane Database Syst Rev. 2006 ;: CD005193
24. Schmidt A, Kometer M, Bachmann R, et al. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl). 2013 ; 225: 227-239
25. Sessa B. Can psychedelics have a role in psychiatry once again?. Br J Psychiatry. 2005 ; 186: 457-458 (Pubitemid 40834862)
26. Sessa B. Is there a case for MDMA-assisted psychotherapy in the UK?. J Psychopharmacol. 2007 ; 21: 220-224 (Pubitemid 46280475)
27. Sessa B. Shaping the renaissance of psychedelic research. Lancet. 2012 ; 380: 200-201
28. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, Maryland: Substance Abuse and Mental Health Services Administration ; 2012:
29. Tenenbaum B. Group therapy with LSD-25. (A preliminary report). Dis Nerv Syst. 1961 ; 22: 459-462
30. Tucker JA, Roth DL. Extending the evidence hierarchy to enhance evidence-based practice for substance use disorders. Addiction. 2006 ; 101: 918-932 (Pubitemid 43847095)
31. Results from the National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration. Inter-university Consortium for Political and Social Research (ICPSR) ; 2013:
32. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci. 2010 ; 11: 642-651